NCT00080795View on ClinicalTrials.gov

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Interventions
BIOLOGICAL

filgrastim

DRUG

cisplatin

DRUG

doxorubicin hydrochloride

DRUG

gemcitabine hydrochloride

DRUG

ifosfamide

PROCEDURE

conventional surgery

PROCEDURE

neoadjuvant therapy

Trial Locations (1)

77030-4009

M.D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00080795 - Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium | Biotech Hunter | Biotech Hunter